Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement-Reference-Cited by-同舟云学术

Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement

Published:2011-04-08 Issue:21 Volume:117 Page:4869-4877
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Mesa Ruben A.,Kantarjian Hagop,Tefferi Ayalew,Dueck Amylou,Levy Richard,Vaddi Kris,Erickson-Viitanen Susan,Thomas Deborah A.,Cortes Jorge,Borthakur Gautam,Pardanani Animesh D.,Estrov Zeev,Verstovsek Srdan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.26129/fullpdf

Reference23 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes;Vardiman;Blood.,2009

2. Myelofibrosis with myeloid metaplasia;Tefferi;N Engl J Med.,2000

3. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients;Mesa;Cancer.,2007

4. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis;Mesa;Leuk Res.,2009

5. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood.,2009

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera;Physiology International;2023-09-05

2. Identifying patient-valued outcomes for use in early phase trials of ocular surface disease interventions;The Ocular Surface;2023-07

3. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy;Leukemia & Lymphoma;2023-04-20

4. Cytopenic myelofibrosis: prevalence, relevance, and treatment;Expert Opinion on Pharmacotherapy;2023-04-17

5. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-09